1 Centre for Infection and Immunity, Queen's University Belfast, Belfast, United Kingdom; and.
2 Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, United Kingdom.
Am J Respir Crit Care Med. 2016 Feb 15;193(4):407-16. doi: 10.1164/rccm.201410-1782OC.
IL-17A is purported to help drive early pathogenesis in acute respiratory distress syndrome (ARDS) by enhancing neutrophil recruitment. Although IL-17A is the archetypal cytokine of T-helper 17 cells, it is produced by a number of lymphocytes, the source during ARDS being unknown.
To identify the cellular source and the role of IL-17A in the early phase of lung injury.
Lung injury was induced in wild-type (C57BL/6) and IL-17 knockout (KO) mice with aerosolized LPS (100 μg) or Pseudomonas aeruginosa infection. Detailed phenotyping of the cells expressing RORγt, the transcriptional regulator of IL-17 production, in the mouse lung at 24 hours was performed by flow cytometry.
A 100-fold reduction in neutrophil infiltration was observed in the lungs of the IL-17A KO compared with wild-type mice. The majority of RORγt(+) cells in the mouse lung were the recently identified group 3 innate lymphoid cells (ILC3s). Detailed characterization revealed these pulmonary ILC3s (pILC3s) to be discrete from those described in the gut. The critical role of these cells was verified by inducing injury in recombinase-activating gene 2 KO mice, which lack T cells but retain innate lymphoid cells. No amelioration of pathology was observed in the recombinase-activating gene 2 KO mice.
IL-17 is rapidly produced during lung injury and significantly contributes to early immunopathogenesis. This is orchestrated largely by a distinct population of pILC3s. Modulation of the activity of pILC3s may potentiate early control of the inflammatory dysregulation seen in ARDS, opening up new therapeutic targets.
白细胞介素 17A(IL-17A)被认为通过增强中性粒细胞募集来帮助驱动急性呼吸窘迫综合征(ARDS)的早期发病机制。尽管 IL-17A 是辅助性 T 细胞 17 细胞的典型细胞因子,但它也由许多淋巴细胞产生,ARDS 期间的来源尚不清楚。
确定 IL-17A 在肺损伤早期的细胞来源和作用。
用气溶胶化脂多糖(100μg)或铜绿假单胞菌感染诱导野生型(C57BL/6)和 IL-17 敲除(KO)小鼠的肺损伤。通过流式细胞术详细表型分析在 24 小时时小鼠肺中表达 RORγt(IL-17 产生的转录调节剂)的细胞。
与野生型小鼠相比,IL-17A KO 小鼠的肺部中性粒细胞浸润减少了 100 倍。在小鼠肺中,大多数 RORγt(+)细胞是最近发现的 3 组固有淋巴细胞(ILC3s)。详细特征分析表明这些肺 ILC3s(pILC3s)与肠道中描述的 ILC3s 不同。通过诱导缺乏 T 细胞但保留固有淋巴细胞的重组激活基因 2 KO 小鼠的损伤,验证了这些细胞的关键作用。在重组激活基因 2 KO 小鼠中未观察到病理学改善。
IL-17 在肺损伤期间迅速产生,并显著促进早期免疫发病机制。这主要由独特的 pILC3 群体协调。调节 pILC3 的活性可能会增强对 ARDS 中所见的炎症失调的早期控制,开辟新的治疗靶点。